Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1987
Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dogG A Kopia, R E Valocik, T J Torphy, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 25, 1992
Preliminary identification and role of phosphodiesterase isozymes in human basophilsP T Peachell, B J Undem, R P Schleimer, et al.British Journal of Pharmacology|December 22, 1999
Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4BC D Manning, M Burman, S B Christensen, et al.The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actionsM S Barnette, S B Christensen, D M Essayan, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|February 1, 1997
Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitorsR N Willette, A O Shiloh, C F Sauermelch, et al.American Journal of Respiratory Cell and Molecular Biology|December 6, 2000
Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphateA J Ammit, R K Hoffman, Y Amrani, et al.The Journal of Pharmacology and Experimental Therapeutics|July 1, 1993
Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipramD C Underwood, R R Osborn, L B Novak, et al.The Journal of Pharmacology and Experimental Therapeutics|November 10, 1998
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivoD E Griswold, E F Webb, A M Badger, et al.Biochemical Pharmacology|April 12, 1996
Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram bindingM S Barnette, J O Bartus, M Burman, et al.The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pigD C Underwood, S Bochnowicz, R R Osborn, et al.Pageof 8